Cargando…
TCR diversity – a universal cancer immunotherapy biomarker?
Sipuleucel-T was approved as a treatment for men with advanced metastatic, castration-resistant prostate cancer on the basis of improved survival in randomized clinical trials. A major challenge for this therapy, as well as other newer cancer immunotherapy agents, has been to identify markers that c...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5109785/ https://www.ncbi.nlm.nih.gov/pubmed/27879971 http://dx.doi.org/10.1186/s40425-016-0175-4 |